UA109109C2 - Кристалічна форма вільної основи бендамустину (варіанти) та фармацевтична композиція для лікування раку (варіанти) - Google Patents

Кристалічна форма вільної основи бендамустину (варіанти) та фармацевтична композиція для лікування раку (варіанти)

Info

Publication number
UA109109C2
UA109109C2 UAA201109971A UAA201109971A UA109109C2 UA 109109 C2 UA109109 C2 UA 109109C2 UA A201109971 A UAA201109971 A UA A201109971A UA A201109971 A UAA201109971 A UA A201109971A UA 109109 C2 UA109109 C2 UA 109109C2
Authority
UA
Ukraine
Prior art keywords
variants
free base
cancer
treatment
pharmaceutical composition
Prior art date
Application number
UAA201109971A
Other languages
English (en)
Russian (ru)
Ukrainian (uk)
Inventor
Лоран Д. Курвуазьє
Марк Еддлстоун
Кертіс Р. Холтіванджер
Роберт Е. Маккін
Original Assignee
Сефалон, Інк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42008533&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA109109(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Сефалон, Інк. filed Critical Сефалон, Інк.
Publication of UA109109C2 publication Critical patent/UA109109C2/uk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/16—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
UAA201109971A 2009-01-15 2010-01-14 Кристалічна форма вільної основи бендамустину (варіанти) та фармацевтична композиція для лікування раку (варіанти) UA109109C2 (uk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14484309P 2009-01-15 2009-01-15
PCT/US2010/020992 WO2010083276A1 (en) 2009-01-15 2010-01-14 Novel forms of bendamustine free base

Publications (1)

Publication Number Publication Date
UA109109C2 true UA109109C2 (uk) 2015-07-27

Family

ID=42008533

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201109971A UA109109C2 (uk) 2009-01-15 2010-01-14 Кристалічна форма вільної основи бендамустину (варіанти) та фармацевтична композиція для лікування раку (варіанти)

Country Status (16)

Country Link
US (1) US8076366B2 (enExample)
EP (1) EP2387400A1 (enExample)
JP (1) JP2012515210A (enExample)
KR (1) KR20110110293A (enExample)
CN (2) CN102281877B (enExample)
AU (2) AU2010204765A1 (enExample)
BR (1) BRPI1004922A2 (enExample)
CA (1) CA2749101A1 (enExample)
EA (1) EA020767B1 (enExample)
IL (1) IL213725A0 (enExample)
MX (1) MX2011007557A (enExample)
NZ (1) NZ594010A (enExample)
SG (1) SG172810A1 (enExample)
UA (1) UA109109C2 (enExample)
WO (1) WO2010083276A1 (enExample)
ZA (1) ZA201105099B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9376394B2 (en) * 2009-12-23 2016-06-28 Dr. Reddy's Laboratories Ltd. Preparation of bendamustine and its salts
PL3158991T3 (pl) 2010-01-28 2021-09-27 Eagle Pharmaceuticals, Inc. Preparaty bendamustyny
EP2720547A4 (en) * 2011-06-20 2014-11-05 Hetero Research Foundation PROCESS FOR BENDAMUSTINE HYDROCHLORIDE
EP4360621A3 (en) 2012-03-20 2024-05-22 Eagle Pharmaceuticals, Inc. Formulations of bendamustine
PT3533447T (pt) 2012-03-20 2023-05-17 Eagle Pharmaceuticals Inc Composições líquidas de bendamustina para utilização num método de tratamento de condições com resposta a bendamustina em pacientes que requerem volumes reduzidos para administração
US20230241218A1 (en) * 2012-07-10 2023-08-03 Eagle Pharmaceuticals, Inc. Formulations of bendamustine
US9598377B2 (en) * 2013-03-12 2017-03-21 Cephalon, Inc. Nanoparticulate and macroparticulate formulations
EP2988655B1 (en) 2013-04-26 2023-04-12 Genentech, Inc. Contour integration perimetry vision test
US20240148696A1 (en) 2022-10-25 2024-05-09 Softkemo Pharma Inc. Lyophilized bendamustine-cyclodextrin composition

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE293808C (enExample)
DE80967C (enExample)
DE159877C (enExample)
DD159289A1 (de) 1981-06-01 1983-03-02 Uwe Olthoff Verfahren zur herstellung stabiler injektionsloesungen von n-lostverbindungen
DD159877A1 (de) * 1981-06-12 1983-04-13 Wolfgang Krueger Verfahren zur herstellung von 4-[1-methyl-5-bis(2-chloraethyl)amino-benzimidazolyl-2]-buttersaeure
US5204335A (en) * 1986-10-31 1993-04-20 Asta Pharma Aktiengesellschaft Ifosfamide lyophilisate and process for its preparation
US5227373A (en) * 1991-10-23 1993-07-13 Bristol-Myers Squibb Co. Lyophilized ifosfamide compositions
RU2139731C1 (ru) * 1992-11-13 1999-10-20 Айдек Фармасьютикалс Корпорейшн (US Способ лечения, антитела, гибридома
US5595721A (en) * 1993-09-16 1997-01-21 Coulter Pharmaceutical, Inc. Radioimmunotherapy of lymphoma using anti-CD20
CN1060042C (zh) * 1993-10-27 2001-01-03 法玛西雅厄普约翰美国公司 稳定的前列腺素e1
US5561121A (en) 1993-11-09 1996-10-01 American Cyanamid Company Stable lyophilized thiotepa composition
US5955504A (en) * 1995-03-13 1999-09-21 Loma Linda University Medical Center Colorectal chemoprotective composition and method of preventing colorectal cancer
DE19529057B4 (de) * 1995-08-08 2007-12-13 Baxter Healthcare S.A. Ifosfamid-Lyophilisat-Zubereitungen
US20040072889A1 (en) * 1997-04-21 2004-04-15 Pharmacia Corporation Method of using a COX-2 inhibitor and an alkylating-type antineoplastic agent as a combination therapy in the treatment of neoplasia
US6034256A (en) * 1997-04-21 2000-03-07 G.D. Searle & Co. Substituted benzopyran derivatives for the treatment of inflammation
US6077850A (en) * 1997-04-21 2000-06-20 G.D. Searle & Co. Substituted benzopyran analogs for the treatment of inflammation
AU767586B2 (en) * 1998-07-09 2003-11-20 Cephalon, Inc. Methods and compositions for the treatment of chronic lymphocytic leukemia
US5972912A (en) * 1998-12-17 1999-10-26 S.P. Pharmaceuticals Method for lyophilizing ifosfamide
US6569402B1 (en) * 1998-12-18 2003-05-27 Bristol-Myers Squibb Pharma Company Vitronectin receptor antagonist pharmaceuticals
US6380210B1 (en) * 1999-04-02 2002-04-30 Neurogen Corporation Heteroaryl fused aminoalkyl-imidazole derivatives: selective modulators of GABAa receptors
US6545034B1 (en) * 1999-07-23 2003-04-08 The Regents Of The University Of California Use of etodolac for the treatment of chronic lymphocytic leukemia
DE10016077A1 (de) 2000-03-31 2001-12-13 Cellcontrol Biomedical Lab Gmb Verfahren und Vorrichtung zum automatischen Nachweisen einer Wirkung eines zellbeeinflussenden Mittels auf lebende Zellen
US20040152672A1 (en) * 2000-08-09 2004-08-05 Carson Dennis A. Indole compounds useful for the treatment of cancer
KR20040025880A (ko) * 2000-12-11 2004-03-26 다케다 야쿠힌 고교 가부시키가이샤 수용해성이 개선된 의약 조성물
AU2002221115A1 (en) * 2000-12-11 2002-06-24 Takeda Chemical Industries Ltd. Medicinal compositions having improved absorbability
CA2462723C (en) * 2001-10-15 2012-05-01 Hemoteq Gmbh Coated stents for preventing restenosis
US6613927B1 (en) 2002-02-08 2003-09-02 American Pharmaceutical Partners, Inc. Sterile lyophilized ifosfamide and associated methods
DE10306724A1 (de) 2002-02-28 2003-09-18 G O T Therapeutics Gmbh Vesikuläre Verkapselung von Bendamustin
WO2003081238A2 (en) 2002-03-22 2003-10-02 Ludwig Maximilians Universität Cytocapacity test
EP1354952A1 (en) 2002-04-17 2003-10-22 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Smac-peptides as therapeutics against cancer and autoimmune diseases
EP1495124A2 (en) 2002-04-17 2005-01-12 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Smac-peptides as therapeutics against cancer and autoimmune diseases
WO2003094990A1 (de) 2002-05-09 2003-11-20 Hemoteq Gmbh Verbindungen und verfahren zur hemokompatiblen beschichtung von oberflächen
AU2003258061A1 (en) * 2002-08-02 2004-02-23 Salmedix, Inc. Therapeutic inhibitionof protein kinases in cancer cells
DE10304403A1 (de) 2003-01-28 2004-08-05 Röhm GmbH & Co. KG Verfahren zur Herstellung einer oralen Arzneiform mit unmittelbarem Zerfall und Wirkstofffreisetzung
EP1444989A1 (en) 2003-02-07 2004-08-11 Giorgio Dr. Stassi Sensitizing cells for apoptosis by selectively blocking cytokines
WO2004074325A2 (en) * 2003-02-14 2004-09-02 Salmedix, Inc Compositions and methods for the detection and treatment of methylthioadenosine phosphorylase deficient cancers
MXPA05013865A (es) * 2003-07-25 2006-02-28 Wyeth Corp Formulaciones liofilizadas de cci-779.
US8436190B2 (en) 2005-01-14 2013-05-07 Cephalon, Inc. Bendamustine pharmaceutical compositions
JP5773874B2 (ja) * 2008-10-08 2015-09-02 セファロン、インク． ベンダムスチンの調製方法

Also Published As

Publication number Publication date
AU2016204902A1 (en) 2016-08-04
MX2011007557A (es) 2011-08-12
AU2010204765A1 (en) 2011-07-28
WO2010083276A1 (en) 2010-07-22
NZ594010A (en) 2013-08-30
ZA201105099B (en) 2012-03-28
US8076366B2 (en) 2011-12-13
CA2749101A1 (en) 2010-07-22
US20100210701A1 (en) 2010-08-19
SG172810A1 (en) 2011-08-29
CN102281877B (zh) 2014-07-23
CN102281877A (zh) 2011-12-14
KR20110110293A (ko) 2011-10-06
JP2012515210A (ja) 2012-07-05
CN103554030A (zh) 2014-02-05
EA020767B1 (ru) 2015-01-30
EA201170934A1 (ru) 2011-12-30
EP2387400A1 (en) 2011-11-23
IL213725A0 (en) 2011-07-31
BRPI1004922A2 (pt) 2019-09-24

Similar Documents

Publication Publication Date Title
UA109109C2 (uk) Кристалічна форма вільної основи бендамустину (варіанти) та фармацевтична композиція для лікування раку (варіанти)
IN2012DN03182A (enExample)
SI2247582T1 (sl) Brezvodna kristalinična oblika dimetoksi docetaksela in postopki za njihovo pripravo
MX339805B (es) Compuestos organicos.
MX2012001974A (es) Compuestos de biarilo y metodos de uso de los mismos.
MY158257A (en) Forms of rifaximin and uses thereof
PH12012501164A1 (en) Imidazopyridine derivatives as jak inhibitors
UA99787C2 (en) Lactams as beta secretase inhibitors
IN2015DN01119A (enExample)
MX340714B (es) Inhibidores de hsp90.
IN2014CN03597A (enExample)
MX2013010898A (es) Novedoso derivados de la pirimidina.
MX2012013274A (es) Novedosos derivados de la pirimidina.
EA201170356A1 (ru) Полиморфные и аморфные формы лакозамида и аморфные композиции
MX2011011083A (es) Compuestos heterociclicos como inhibidores de mek.
MX2013002329A (es) Agonista de receptores de neutrofina y sus usos como medicamentos.
MX354691B (es) Una forma cristalina de clorhidrato de (r)-7-cloro-n-(quinuclidin- 3-il)benzo[b]tiofeno-2-carboxamida monohidratado.
IN2012DN03042A (enExample)
PH12017500089A1 (en) Aldosterone synthase inhibitors
MX2010009756A (es) Agonistas de receptores muscarinicos, composiciones, metodos de tratamiento de los mismos, y proceso para preparacion de los mismos.
MX2011012859A (es) Formas cristalinas de 6-(1h-imidazol-1-il)-2-fenilquinazolina.
IN2013DN02555A (enExample)
MX367327B (es) Formulaciones, sales y polimorfos de transnorsertralina y usos de los mismos.
WO2011125006A3 (en) Sultam compounds
SI2184072T1 (sl) Proizvodnja homogenega vakcinskega pripravka za zdravljenje raka